| Recruiting | Vitamin D Treat-to-Target Strategy for Children With Overactive Bladder-Wet NCT06201013 | Children's Hospital of Chongqing Medical University | N/A |
| Not Yet Recruiting | Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Ge NCT07227285 | EG 427 | Phase 1 / Phase 2 |
| Recruiting | Ambulatory Long Length URodynamics Evaluation NCT07425015 | Bright Uro | N/A |
| Not Yet Recruiting | A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections NCT07387315 | TriHealth Inc. | Phase 4 |
| Recruiting | Comparison of the Efficacy of Perineal and Intravaginal Electrical Stimulation in Women With Idiopathic Overac NCT07366918 | Pamukkale University | N/A |
| Not Yet Recruiting | The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Auto NCT07114640 | Far Eastern Memorial Hospital | Phase 3 |
| Not Yet Recruiting | Transcutaneous Medial Plantar Nerve Stimulation in Women With Idiopathic Overactive Bladder NCT06390488 | Pamukkale University | N/A |
| Completed | Efficacy of Animated Videos to Foster Healthy Bladder Behaviors in Community Women NCT06921915 | Kathleen O'Connell | N/A |
| Recruiting | Elastographic Assessment of Suburethral Tissue in Continent and Incontinent Women NCT06933407 | Szeged University | — |
| Recruiting | NXT Post-Market Clinical Follow-up NCT06336304 | Laborie Medical Technologies Inc. | — |
| Not Yet Recruiting | Transcutaneous Tibial Nerve Stimulation in Patients With Neurogenic Overactive Bladder After Stroke NCT06385769 | Pamukkale University | N/A |
| Unknown | Comparison of the Efficacy of Transcutaneos Nerve Stimulations in Women With Idiopathic Overactive Bladder NCT06349694 | Pamukkale University | N/A |
| Completed | Association With Low Compliance Bladder in Women With LUTS NCT06210477 | National Taiwan University Hospital | — |
| Unknown | Effectiveness of Oral Boldo in Women With Overactive Bladder NCT06162065 | Universidad de Valparaiso | Phase 1 |
| Active Not Recruiting | Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls NCT05880862 | The University of Texas Medical Branch, Galveston | EARLY_Phase 1 |
| Active Not Recruiting | Wearables for the Bladder: an In-home Treatment Feasibility Pilot Study NCT05715268 | University of California, San Francisco | N/A |
| Unknown | Transcutaneous Tibial Nerve Stimulation in Antimuscarinic Naive and Refractory Women With Idiopathic Overactiv NCT05668715 | Pamukkale University | N/A |
| Unknown | The Efficacy of Intravaginal Electrical Stimulation in Women With Idiopathic Overactive Bladder NCT05416450 | Pamukkale University | N/A |
| Terminated | INvestigation of TENS Efficacy Versus Posterior Tibial Nerve Stimulation for Overactive Bladder NCT05309993 | University of New Mexico | N/A |
| Recruiting | Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bl NCT06479720 | Mackay Memorial Hospital | Phase 4 |
| Recruiting | Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Ov NCT06197295 | Mackay Memorial Hospital | Phase 4 |
| Active Not Recruiting | INTIBIA Pivotal Study NCT05250908 | Coloplast A/S | N/A |
| Recruiting | Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Over NCT05968885 | Mackay Memorial Hospital | Phase 4 |
| Unknown | BOTOX® at the Time of Prolapse Surgery for OAB NCT04807920 | Walter Reed National Military Medical Center | Phase 4 |
| Withdrawn | Direct Full-stage Implantation of Sacral Neuromodulation NCT03697954 | Loma Linda University | — |
| Unknown | Targeting Microbiota in Female Overactive Bladder Syndrome NCT05328011 | Medical University of Vienna | — |
| Completed | Feasibility Study of Transcutaneous Tibial Nerve Stimulation for Urinary Symptoms in People With Multiple Scle NCT04528784 | University of Limerick | N/A |
| Completed | Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron in Sexually Active Men With OA NCT04420533 | Chang Gung Memorial Hospital | N/A |
| Recruiting | Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A NCT04305743 | University of South Florida | Phase 4 |
| Completed | Pilot Phase for an Acute Evaluation of a Non-Implantable Electrical Continence Device NCT04001426 | FemPulse Corporation | N/A |
| Completed | FemPulse Therapy for Overactive Bladder in Women NCT03784170 | FemPulse Corporation | N/A |
| Completed | Laser Therapy for Treatment of Urogenital Symptoms in Women NCT03681678 | Corewell Health East | — |
| Terminated | OnabotulinumtoxinA Bladder Injection Study NCT03523091 | Corewell Health East | Phase 4 |
| Completed | Fluids Affecting Bladder Urgency and Lower Urinary Symptoms NCT03625492 | University of Michigan | N/A |
| Completed | Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC) NCT03043287 | Allergan | — |
| Completed | FemPulse Therapy First-in-Human Experience NCT03874637 | FemPulse Corporation | N/A |
| Completed | Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive NCT03052764 | Allergan | Phase 4 |
| Completed | Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detru NCT02849418 | GlaxoSmithKline | Phase 3 |
| Terminated | Fesoterodine on Urgency Episodes in Parkinson's Disease Population NCT02385500 | Sir Mortimer B. Davis - Jewish General Hospital | Phase 4 |
| Completed | Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder NCT02820844 | GlaxoSmithKline | Phase 3 |
| Terminated | Electrostimulation in the Treatment of Idiopathic Overactive Bladder NCT03519126 | Janaina Mayer de Oliveira Nunes | N/A |
| Completed | Urodynamic Testing: Can we Improve Patient Experience? NCT02742389 | Boston Urogynecology Associates | N/A |
| Completed | Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontinence Associated With Overactive NCT02673047 | Allergan | — |
| Unknown | Brain Areas Involved in Bladder Filling and Contraction NCT02477241 | Maastricht University Medical Center | N/A |
| Completed | Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive NCT02557971 | Allergan | — |
| Terminated | Overactive Bladder Education NCT02505607 | Hartford Hospital | N/A |
| Terminated | Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement NCT02462837 | Southern Illinois University | Phase 2 |
| Completed | A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment NCT02386072 | Astellas Scientific & Medical Affairs, Inc. | — |
| Completed | IVES for Treatment of UUI and OAB NCT02992509 | Loma Linda University | EARLY_Phase 1 |
| Completed | A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Rou NCT02320773 | Astellas Pharma Europe Ltd. | — |
| Completed | An Observational Study of BOTOX® for the Management of Urinary Incontinence in Patients With Idiopathic Overac NCT02161159 | Allergan | — |
| Completed | A Study to Evaluate Quality of Life in Patients Switched to Solifenacin From Other Antimuscarinics NCT02087098 | Astellas Pharma Europe B.V. | — |
| Completed | Comparisons of Urodynamic, Bladder Diary, Quality of Life Parameters Between OAB-wet and OAB-dry Female Patien NCT03560778 | National Taiwan University Hospital | — |
| Completed | A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and NCT02045862 | Astellas Pharma Europe B.V. | Phase 3 |
| Unknown | Effects of TENS in Autonomous System in Women With Overactive Bladder NCT02456441 | Federal University of Health Science of Porto Alegre | N/A |
| Completed | Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neur NCT02010788 | Allergan | — |
| Completed | Use of Medium Frequency Electrotherapy in the Treatment of OAB, LUTS and Pelvic Pain NCT03520166 | Fisioterapia Pélvica Avanzada Madrid, SRL | N/A |
| Completed | This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and NCT01972841 | Astellas Pharma Europe B.V. | Phase 3 |
| Completed | A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) NCT01908829 | Astellas Pharma Europe Ltd. | Phase 3 |
| Completed | The Effect of Anticholinergics on Cognitive Function in the Elderly NCT01922115 | University of North Carolina, Chapel Hill | Phase 4 |
| Completed | Behavioural Therapy Program for Female Overactive Bladder NCT02701010 | Saglik Bilimleri Universitesi Gulhane Tip Fakultesi | N/A |
| Completed | Unilateral Versus Bilateral Neuromodulation Tests in the Treatment of Refractory Idiopathic Overactive Bladder NCT01558856 | Centre Hospitalier Universitaire de Nīmes | N/A |
| Completed | A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Sy NCT01655069 | Astellas Pharma Europe B.V. | Phase 3 |
| Completed | Prevention of Bladder Dysfunction in Acute Spinal Cord Injury NCT01698138 | Oslo University Hospital | Phase 4 |
| Unknown | Management of the Idiopathic Overactive Bladder With Botulinum Toxin: Systematic Review NCT01750645 | Clínica Infantil Colsubsidio | — |
| Completed | A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive NCT01638000 | Astellas Pharma Europe Ltd. | Phase 3 |
| Completed | A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolesc NCT01565707 | Astellas Pharma Europe B.V. | Phase 3 |
| Completed | A Study To Estimate The Effects Of Food On Drug Fesoterodine Fumarate And The Pharmacokinetics Of 5-Hydroxymet NCT01566760 | Pfizer | Phase 1 |
| Unknown | Solifenacin Succinate Versus Fesoterodine A Comparison Trial for Urgency Symptoms NCT01595152 | Rambam Health Care Campus | N/A |
| Unknown | Study of Overactive Bladder in Women With Prolapse NCT01540214 | Radboud University Medical Center | — |
| Completed | Pharmacokinetics and Relative Bioavailability Study NCT01521767 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 1 |
| Completed | A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesot NCT01302054 | Pfizer | Phase 4 |
| Completed | A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-461 NCT01314872 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in NCT01340027 | Astellas Pharma Europe B.V. | Phase 2 |
| Terminated | Non-Interventional Study To Investigate Whether Information Provided To Patients Influences Their Satisfaction NCT01091519 | Pfizer | — |
| Completed | Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents NCT01262391 | Astellas Pharma Inc | Phase 1 |
| Completed | Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symp NCT01381120 | Barrie Urology Associates | Phase 4 |
| Completed | Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinenc NCT01157377 | Allergan | Phase 2 |
| Completed | Evaluating the Change of Overactive Bladder Symptoms in Women Post Pubovaginal Sling Procedure for Stress Inco NCT01194999 | Barrie Urology Associates | Phase 4 |
| Completed | Cohort Study: Perceptual Urge Sensation NCT00971646 | Maastricht University Medical Center | — |
| Completed | Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overact NCT01054222 | Pfizer | Phase 4 |
| Completed | A Study of YM178 in Subjects With Symptoms of Overactive Bladder NCT01043666 | Astellas Pharma Inc | Phase 3 |
| Completed | Evaluation of Adherence to Solifenacin Treatment in Overactive Bladder Patients NCT00985387 | Astellas Pharma Inc | — |
| Completed | A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder NCT00966004 | Astellas Pharma Inc | Phase 3 |
| Completed | Age-specific Prevalence and Comparisons of UDS and Bladder Diary Between OAB-wet and -Dry Women NCT03807024 | National Taiwan University Hospital | — |
| Completed | The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects NCT00914667 | Pfizer | Phase 1 |
| Completed | A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of NCT00912964 | Astellas Pharma Inc | Phase 3 |
| Completed | Solifenacin Flexible Dosing Study in Frequent Micturition Patients With and Without Urgency NCT00979472 | Asan Medical Center | Phase 4 |
| Completed | UK Study Assessing Flexible Dose Fesoterodine in Adults NCT00806494 | Pfizer | Phase 4 |
| Completed | Modified Extension Study to the SUmiT Trial: Evaluation of Long Term Therapy With Percutaneous Tibial Nerve St NCT00928395 | Uroplasty, Inc | Phase 4 |
| Completed | A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients NCT00840645 | Astellas Pharma Inc | Phase 3 |
| Terminated | Pulsed Electromagnetic Stimulation for Treatment of Overactive Bladder NCT00805779 | EMKinetics, Inc | N/A |
| Completed | A Randomized, Double-Blinded, Placebo-Controlled, Two-Way Crossover Study to Investigate the Safety and Tolera NCT00814736 | Pfizer | Phase 1 |
| Completed | 516-BOTOX Urinary Incontinence Detrusor NCT00850733 | Veterans Medical Research Foundation | — |
| Completed | A Study Comparing the Efficacy of an Alpha Blocker Versus an Alpha Blocker Plus Solifenacin in Men With Overac NCT00699049 | KYU-SUNG LEE | Phase 4 |
| Completed | A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patien NCT00798434 | Pfizer | Phase 4 |
| Completed | Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of NCT00689104 | Astellas Pharma Inc | Phase 3 |
| Completed | Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symp NCT00688688 | Astellas Pharma Inc | Phase 3 |
| Completed | A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Ov NCT00662909 | Astellas Pharma Inc | Phase 3 |
| Completed | A Study of YM178 in Patients With Symptomatic Overactive Bladder NCT00527033 | Astellas Pharma Inc | Phase 2 |
| Completed | An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactiv NCT00613327 | Janssen Korea, Ltd., Korea | Phase 4 |
| Completed | Special Investigation For Long Term Use Of Tolterodine (Regulatory Post Marketing Commitment Plan). NCT00795509 | Pfizer | — |
| Completed | Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality NCT00573508 | Astellas Pharma Inc | Phase 4 |
| Completed | Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive Bladder NCT00479505 | Pfizer | Phase 2 |
| Completed | A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder NCT00368706 | Astellas Pharma Inc | Phase 3 |
| Completed | Linkage Analysis in Interstitial Cystitis NCT00675298 | Beth Israel Deaconess Medical Center | — |
| Completed | Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for NCT00454740 | Astellas Pharma Inc | Phase 3 |
| Completed | Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms NCT00463541 | Astellas Pharma Inc | Phase 3 |
| Completed | A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Blad NCT00454896 | Astellas Pharma Inc | Phase 3 |
| Completed | Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder NCT01604928 | Astellas Pharma Europe B.V. | Phase 2 |
| Completed | Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency Symptoms NCT00801944 | Astellas Pharma Inc | Phase 3 |
| Completed | A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder NCT00645281 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 4 |
| Completed | Solifenacin Succinate Versus Tolterodine 4mg Once Daily NCT00802373 | Astellas Pharma Inc | Phase 3 |
| Completed | A Study to Evaluate the Efficacy of Tolterodine Prolonged Release Compared With Propiverine for the Treatment NCT00646880 | Pfizer | Phase 3 |